Celcuity Inc.

XNASHealth care

Last traded price · USD

$67.34

−2.75%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $68.28
Previous close: $69.24
Volume: 75,820
Day's high: $68.77
Day's low: $66.01

In brief

Celcuity Inc. is a health care company listed on Nasdaq, valued at about $3.29B.
Its shares closed at $69.24 on 4 Nov 2026, down 5.1% over the past year.
From India you can buy CELC in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Celcuity Inc. (CELC) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole CELC share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade CELC options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −2.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.5% (SPY −0.4%, XLV +15.5%). 1 year: −5.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CELC, SPY and XLV · as of 4 Nov 2026
5.8 days to cover short interest
10.3M shares were sold short at the 15 Oct 2026 settlement, 21.0% of the 48.9M shares outstanding; covering them would take 5.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $69.24 was 9.2% below its 50-day average ($76.26) and 30.8% below its 200-day average ($100.07). It has closed below the 200-day for 80 sessions, since 15 Jul 2026. The 50-day average crossed below the 200-day on 29 Jul 2026, 69 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
16% of the way up its 52-week range
Closed at $69.24 on 4 Nov 2026: 54.2% below the 52-week high of $151.02 (4 May 2026) and 29.3% above the low of $53.54 (16 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.8%

6 months−50.3%

1 year−5.1%

5 years+267.3%

Newswire

About

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Website

Notable moves

October 20, 2025
+35.84%
July 28, 2025
+167.18%
December 19, 2022
+29.97%

Newswire

About

Website

Notable moves

October 20, 2025
+35.84%
July 28, 2025
+167.18%
December 19, 2022
+29.97%

Celcuity Inc.

XNASHealth care

Last traded price · USD

$67.34

−2.75%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $68.28
Previous close: $69.24
Volume: 75,820
Day's high: $68.77
Day's low: $66.01

In brief

Celcuity Inc. is a health care company listed on Nasdaq, valued at about $3.29B.
Its shares closed at $69.24 on 4 Nov 2026, down 5.1% over the past year.
From India you can buy CELC in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Celcuity Inc. (CELC) shares from India?

Do I need the price of a whole CELC share to invest?

How much can I invest in US stocks in a year?

Can I trade CELC options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −2.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.5% (SPY −0.4%, XLV +15.5%). 1 year: −5.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CELC, SPY and XLV · as of 4 Nov 2026
5.8 days to cover short interest
10.3M shares were sold short at the 15 Oct 2026 settlement, 21.0% of the 48.9M shares outstanding; covering them would take 5.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $69.24 was 9.2% below its 50-day average ($76.26) and 30.8% below its 200-day average ($100.07). It has closed below the 200-day for 80 sessions, since 15 Jul 2026. The 50-day average crossed below the 200-day on 29 Jul 2026, 69 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
16% of the way up its 52-week range
Closed at $69.24 on 4 Nov 2026: 54.2% below the 52-week high of $151.02 (4 May 2026) and 29.3% above the low of $53.54 (16 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.8%

6 months−50.3%

1 year−5.1%

5 years+267.3%

Newswire

About

Website

Notable moves

October 20, 2025
+35.84%
July 28, 2025
+167.18%
December 19, 2022
+29.97%

Newswire

About

Website

Notable moves

October 20, 2025
+35.84%
July 28, 2025
+167.18%
December 19, 2022
+29.97%

Celcuity Inc.

Celcuity Inc. in brief

Behind SPY and its sector fund XLV over 1 year

5.8 days to cover short interest

Below its 50- and 200-day averages

16% of the way up its 52-week range

Celcuity Inc.

Celcuity Inc. in brief

Behind SPY and its sector fund XLV over 1 year

5.8 days to cover short interest

Below its 50- and 200-day averages

16% of the way up its 52-week range